We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Imaging Significantly Underestimates the Size of DCIS Tumors

By HospiMedica International staff writers
Posted on 15 Apr 2021
A new study suggests that pre-operative imaging of high-volume ductal carcinoma in situ (DCIS) lesion size is inaccurate. More...


Researchers at the University of British Columbia (UBC; Vancouver, Canada), Western University (UWO; London, Canada), and Mount Saint Joseph Hospital (Vancouver, Canada) undertook a retrospective review of clinicopathologic data of patients treated for DCIS with breast conserving surgery (BCS) between 2012 and 2018. Mammographic and sonographic lesion sizes were compared with final pathology sizes.

The results showed that for 152 lesions visible on mammography, mean size on imaging was significantly smaller when compared to final pathology (2.3 centimeters versus 3.6 centimeters, respectively); the mean difference of 1.3 cm was a significant underestimation, with a correlation coefficient of 0.367. For the 48 lesions visible on ultrasound, the radiologic size was significantly smaller than pathologic size (1.7 centimeters versus 4.1 centimeters, respectively), but degree of underestimation was not significantly correlated. The study was published on March 23, 2021, in The American Journal of Surgery.

“Imaging size of DCIS tumors assessed by both mammography and ultrasound were significantly smaller when compared with their final size on pathology,” concluded lead author Rachel Liu, MD, of UWO, and colleagues. “Increase in the degree of underestimation by mammography was noted as the histological tumor size increased. This must be taken into consideration during surgical planning for maximizing the success of breast conserving surgery and minimizing return to the operating room.”

DCIS is the most common type of non-invasive breast cancer, in which the abnormal cells are contained inside the milk ducts. If DCIS is not treated, it may eventually develop into invasive breast cancer, which can spread outside the ducts into the breast tissue and then possibly to other parts of the body. Since DCIS cannot usually be felt as a breast lump or other breast change, most cases are diagnosed following routine screening with mammograms or ultrasound, appearing as micro-calcifications.

Related Links:
University of British Columbia
Western University
Mount Saint Joseph Hospital



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Glucose Meter
StatStrip®
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image Credit: Adobe Stock

Noninvasive Imaging Approach Aims to Detect Basal Cell Carcinoma Before It Becomes Visible

Basal cell carcinoma is the most common form of skin cancer and can damage nearby structures such as the nose or eyes when it develops on the face. Diagnosis typically depends on visible skin changes,... Read more

Surgical Techniques

view channel
Image: Associate Professor Menglin Chen studies how the light-sensitive nanoparticles affect living cells. The screen shows calcium being released inside a cell after nanoparticles taken up by the cell are exposed to blue light. Calcium plays an important role in cellular signaling, and the experiment helps the researchers understand how the nanoparticles can translate light into biological activity. (Photo courtesy of Aarhus University, Johanne Holm Jensen)

Light-Activated Nanoparticles May Offer New Approach to Retinal Prostheses

Retinitis pigmentosa is a degenerative retinal disorder in which photoreceptors progressively die, reducing visual signals to the brain while leaving surviving inner retinal circuits underused.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.